ACOG
Alpha Cognition Inc.
$7.90
+0.01 (+0.13%)
At close · Jul 6
Market Cap
$171.91M
Shares
21,774,104
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$7.90
Open$8.17
Day$7.65–8.21
52W$4.50–11.54
Avg vol 30d40K
Short int174K · 0.8% float · 5.9d
Short vol54%
Last earningsMar 31, 2026
DataNov 2024–Jul 2026
Filing10-Q · May 14
Equibles Rating
blended score · not investment advice
Overall
Buy
Technical · trend & momentum
Buy
+
50 / 200-day cross
golden cross
+
Price vs 200-day avg
+28% above
+
Price vs 50-day avg
+26% above
−
RSI (14)
77 · overbought
+
MACD trend
positive
◦
52-week position
48% · mid-range
Sentiment · smart money
Bullish
+
Trend (MA cross)
50d $6 › 200d $6 — 50d above 200d
−
Institutional flow
-7% holders QoQ · +3 funds added
+
Insider flow
Net +$2.1M over 90 days · 0% sells
+
Short interest
0.80% of float · ▼ -1.5% MoM · 5.9 days cover
◦
Volume signal
Volume near normal
◦
Institution breadth
25 holders — mid 1-yr range
Fundamentals
Fair
−
Revenue growth
−90% Y/Y
+
EPS growth
+42% Y/Y
−
Free cash flow
$-20.7M
+
Balance sheet
net cash $66.0M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 14, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Guidance & track record
Latest guidance
· from the Earnings Call filed Mar 31, 2026
Full year 2026 operating expense
· full year 2026
Initiated
$54M – $58M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
golden cross
Bullish
Price vs 200-day avg
+28% above
Bullish
Price vs 50-day avg
+26% above
Bullish
RSI (14)
77 · overbought
Bearish
MACD trend
positive
Bullish
52-week position
48% · mid-range
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
Golden cross
50d $6 › 200d $6 — 50d above 200d
Institutional flow
Distributing
-7% holders QoQ · +3 funds added
Insider flow
Accumulating
Net +$2.1M over 90 days · 0% sells
Short interest
Falling
0.80% of float · ▼ -1.5% MoM · 5.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
25 holders — mid 1-yr range
Price context
position in its 52-week range
52-wk low $5
Now $8 · 48%
52-wk high $12
vs 200-day avg +28%
vs 50-day avg +26%
50-day above 200-day golden cross
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| bottles dispensed in March | 2,321 | Q1 2026 call | — |
| HCP writers | 1,060 | Q1 2026 call | — |
| homes with ZUNVEYL prescriptions | 914 | Q1 2026 call | — |
| prescribers called on | 3,762 | Q1 2026 call | — |
| total bottles dispensed | 6,054 | Q1 2026 call | — |
| total health care providers reached | 7,900 | Q1 2026 call | — |
| unique nursing homes called on | 2,502 | Q1 2026 call | — |
| ZUNVEYL price | $869.36 | Q1 2026 call | — |
| Bottles Dispensed | 4,941 | Q4 2025 | — |
| Bottles Dispensed (December) | 1,859 | December 2025 | — |
| Bottles dispensed quarter-over-quarter growth | 62% | Q4 2025 | — |
| Cumulative homes with prescriptions increase | 26% | Q4 2025 | — |
| Homes reached | 1,986 | Q4 2025 | — |
| Q4 prescribers increase | 50% | Q4 2025 | — |
| Unique facilities engaged since commercial launch | 4,000 | Launch-to-date | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ACOG
this stock
Alpha Cognition Inc.
|
$171.91M | +21.5% | — | — | 0.8% |
|
ONC
BeOne Medicines Ltd.
|
$488.96B | +1.9% | +22179.2% | 995.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$132.92B | +16.8% | +46.2% | 31.1 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.33B | -15.7% | +20.8% | 16.1 | 3.2% |
|
ARGX
Argenx SE
|
$57.87B | +9.0% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ACOG | +21.5% | +33.7% | +21.0% | +9.4% | +21.5% |
| SPY | +3.1% | -0.8% | +8.2% | +0.6% | +10.2% |
| vs SPY | +18.5% | +34.4% | +12.7% | +8.8% | +11.4% |